Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6509283 | 0.88 | CDK1 (0.78) | CDK1KDR | |
| SCHEMBL6509702 | 0.87 | CDK1 (0.83) | CDK1KDR | |
| SCHEMBL6510459 | 0.85 | CDK1 (0.74) | CDK1KDR | |
| SCHEMBL6514284 | 0.84 | CDK1 (1.00) | CDK1KDR | |
| SCHEMBL6509488 | 0.83 | CDK1 (0.98) | CDK1KDR | |
| SCHEMBL6511860 | 0.83 | CDK1 (1.00) | CDK1KDR | |
| SCHEMBL6509042 | 0.83 | CDK1 (0.70) | CDK1KDR | |
| SCHEMBL6513906 | 0.82 | CDK1 (0.71) | CDK1KDR | |
| SCHEMBL6511996 | 0.82 | CDK1 (0.71) | CDK1KDR | |
| SCHEMBL6509985 | 0.82 | CDK1 (0.86) | CDK1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1222175-B1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LTD (GB) | 2005-12-14 | — | — | EP | claimed |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | DAVIS JEREMY MARTIN (GB) | 2003-11-13 | — | — | US | claimed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | claimed |
| EP-1222175-B1 | 4,5-DISUBSTITUTED-2-AMINOPYRIMIDINES | CELLTECH R&D LTD (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2005-08-04 | — | — | US | disclosed |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | CELLTECH R&D LIMITED | 2004-11-25 | — | — | US | disclosed |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | DAVIS JEREMY MARTIN (GB) | 2003-11-13 | — | — | US | disclosed |
| US-6600037-B1 | The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis. | CELLTECH R & D LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171134-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FLT4, FGFR1 | CDK1 435/4885KDR 8/4885 |
| US-20030212269-A1 | 4.5-disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | CDK1 961/4885KDR 7/4885 |
| US-20040235876-A1 | 4,5-Disubstituted-2-aminopyrimidines | FLT1, FGFR1, FLT4 | CDK1 956/4885KDR 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.